

**Currently Open Paediatric AYA Haematology/Oncology Clinical Trials
(as at April 2019)**

Protocol number /name	Protocol description	Age range	Criteria	Specialist Centre (s)
ACCT007	Phase I Study of Vinorelbine, Cyclophosphamide and Rapamycin for Recurrent Malignancies in Children.	< 22 years	Solid tumour malignancy, relapse/refractory, no curative therapy.	Starship Children's Hospital/ Christchurch Hospital
ANZCHOG NORTH (Panobinostat) Study	Panobinostat in solid tumours including osteosarcoma, malignant rhabdoid tumour/ ATRT and neuroblastoma.	All AYA	Eligibility varies.	Starship Children's Hospital/ Christchurch Hospital
ANZUP P3 BEP	Accelerated BEP. Germ cell tumour. Intermediate and poor risk.	11 years - 45 years		Starship Children's Hospital/ Christchurch Hospital
AALL1131	High Risk. HR pre-B ALL.	> 365 days and < 31 years of age		Starship Children's Hospital/ Christchurch Hospital
AALL1231	T Cell ALL / T-NHL	> 1 year and < 31 years		Starship Children's Hospital/ Christchurch Hospital
AALL1631	Ph+ve ALL	> 1 year and ≤ 21 years old	>1 year and ≤21 years old, newly diagnosed B-ALL or T-ALL with BCR-ABL fusion. Must have diagnostic bone marrow available.	Starship Children's Hospital/ Christchurch Hospital
ACNS0831	Post Radiation Chemotherapy in Ependymoma.	> 12 months and < 21 years of age	Diagnosis of ependymoma - histologically confirmed.	Starship Children's Hospital/ Christchurch Hospital
ALTE1621	Reversal of Ventricular Remodelling in Child Cancer Survivors at Risk for Heart Failure. Late Effects Study.	Cancer diagnosis < 22 years of age	Cancer diagnosis <22 yrs of age + lifetime anthracycline dose of ≥250mg/m2 doxorubin equivalent without dezradoxane protection.	Starship Children's Hospital/ Christchurch Hospital
APEC14B1	Project EveryChild, COG Registry & banking study.	≤ 25 years.	≤ 25 years at diagnosis. Non-treatment registry and specimen banking study.	Starship Children's Hospital/ Christchurch Hospital
ARST1431	Temsirolimus in IR Rhabdomyosarcoma	< 40 years	IR RMS.	Starship Children's Hospital/ Christchurch Hospital
ASSET Registry	ASSET Registry - ANZCHOG	≤ 18 years	Registry study - Subtype and Side Effects of Treatment. Australasian.	Starship Children's Hospital/ Christchurch Hospital
COG AALL1331	Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	≥ 1 year and < 31 years of age at the time of relapse	First relapse B-ALL; must meet organ function and prior therapy criteria; tissue submission requirements.	Starship Children's Hospital/ Christchurch Hospital
COG ACNS0831	Ependymoma Newly Diagnosed.	1 year - 21 years	Histologically confirmed intracranial ependymoma non-metastatic.	Starship Children's Hospital
COG AGCT1531	Active Surveillance for LR and Randomised Trial of Carboplatin vs Cisplatin for SR (SR & LR Germ Cell Tumours).	LR < 50 years, SR1 < 11 years, SR2 ≥ 11 & < 25 years	Newly diagnosed with primary extracranial GCT.	Starship Children's Hospital/ Christchurch Hospital
EuroNET PHL-C2	Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents.	< 25 years	Newly diagnosed classical HL, histologically confirmed. Tissue submission requirements.	Starship Children's Hospital/ Christchurch Hospital
Future Fertility	FUTuRE Fertility - Australasian Oncofertility Registry	0-24 years	0-12 years: those who pursue fertility preservation; 13-24 years: all regardless of fertility input.	Christchurch Hospital
IntReALL SR	International Study of Treatment of Standard Risk Childhood Relapsed ALL 2010	< 18 years	SR relapsed ALL; tissue submission requirements.Successor to ALLR3. Precursor B-cell or T-cell ALL.	Starship Children's Hospital/ Christchurch Hospital

**Currently Open Paediatric AYA Haematology/Oncology Clinical Trials
(as at April 2019)**

Protocol number /name	Protocol description	Age range	Criteria	Specialist Centre (s)
LCH-IV	International Treatment for LCH (Phase III Langerhans Cell Histiocytosis).	< 18 years	LCH diagnosis, no prior systemic therapy.	Starship Children's Hospital/ Christchurch Hospital
MK3475-913	Pembrolizumab as first line therapy in participants with Advanced Merkel Cell Carcinoma	> 12 years	Histologically confirmed Advanced Merkel Cell Carcinoma.	Auckland (Dr Ben Lawrence)
MNP 2.0	Molecular Neuropathy 2.0. Increasing diagnostic accuracy in paediatric neuro-oncology .	Any age		Starship Children's Hospital/ Christchurch Hospital
Myechild 01	Phase III. De Novo AML.	> 1 year and < 18 years		Starship Children's Hospital/ Christchurch Hospital
Ovarian Tissue Protocol	Ovarian Tissue Cryopreservation/Banking Protocol for New Zealand Paediatric Haematology/Oncology Services	0-18 years	Must meet disease, prognosis and risk criteria per protocol	Starship Children's Hospital/ Christchurch Hospital
rEECur	Ewings sarcoma - recurrent & primary refractory.	≥ 4 years and <50 years		Christchurch Hospital
SJMB12	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma	≥ 3 years and < 22 years	Confirmed dx of medulloblastoma; tissue submission requirements; no prior therapy	Starship Children's Hospital

Note:

List of currently open therapeutic studies which include the AYA age range in eligibility criteria.

Studies open at time of writing.

Auckland: Please call Starship Lead CRA Sarah Hunter (027 264 3502) or Starship AYA Oncologist Mark Winstanley (021 938 430) to discuss potential inclusion on study.

Christchurch: Please call CHOC Lead CRA Sara Parkin (021 136 2135) or CHOC AYA Oncologist Tristan Pettit (027 886 2142)

Last updated April 2019.